AMGEN INC

Amgen’s proxy reveals gains in FDA approvals, R&D focus on biologics, and cautious capital plans—yet faces pricing pressure, high attrition, and delayed manufacturing ROI.

Amgen’s 2025 revenue rises 13.4% with new Horizon Therapeutics assets and five FDA approvals, positioning 2026 for a $2.3B U.S. manufacturing boost and $650M pipeline expansion.

Repatha cuts first major cardiovascular events by ~30% in high‑risk diabetics with high LDL‑C, proving it’s a powerful, safe second‑line option when statins fall short.

Amgen’s strong financials and pipeline position it to capture 5–7 % of the $30 bn GLP‑1 market by 2035, offering investors a growing upside amid rising diabetes and obesity rates.

Amgen’s stock rises as breakthrough CRISPR‑CAR‑T for pancreatic cancer and an ADC for CKD gain FDA designations, promising new revenue streams and investor confidence.

Amgen’s stock rebounds as analyst upgrades and a robust therapy pipeline—including CAR‑T and kinase inhibitors—boost investor confidence and signal strong growth prospects.

Amgen’s steady share price, backed by solid earnings and promising biotech pipeline, shows potential upside as Phase 3 data for AMG 301, AMG 701, and AMG 510 emerge.

Amgen’s latest investor activity shows institutional confidence amid a downgrade, highlighting pipeline strengths, pricing pressures and patent risks.

Amgen’s $840 m purchase of Dark Blue Therapeutics adds a promising small‑molecule AML candidate to its pipeline, positioning the company for premium pricing, patent protection, and a 4‑5‑year market launch in the $4.3 bn AML space.

Amgen’s modest Fitch upgrade reflects solid debt ratios and new U.S. government partnership, yet rising biosimilar competition could pressure margins and spark strategic shifts in pricing, production, and diagnostics.